<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742283</url>
  </required_header>
  <id_info>
    <org_study_id>012604IN</org_study_id>
    <nct_id>NCT04742283</nct_id>
  </id_info>
  <brief_title>Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <acronym>ANGEL-2</acronym>
  <official_title>A Phase IIb, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop&#xD;
      medications has been shown to be effective in delaying or preventing the progression of&#xD;
      glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field&#xD;
      loss.&#xD;
&#xD;
      This study is being conducted to determine how well DE-126 ophthalmic solution works&#xD;
      (efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate&#xD;
      the safety and efficacy of DE-126, ophthalmic solution in subjects with Primary Open Angle&#xD;
      Glaucoma (POAG) or Ocular Hypertension (OHT).&#xD;
&#xD;
      The IOP will be measured at 3 different times throughout the day, over 4 total visits during&#xD;
      a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop&#xD;
      taking current eye drops to lower IOP). Safety assessments will be done throughout the study,&#xD;
      including ocular signs and symptoms, and vital signs. While the most important time-point to&#xD;
      measure IOP in this study and evaluate efficacy will be at the final study visit (month 3),&#xD;
      IOP values will also be evaluated at other visits throughout the 3-month treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>08:00, 10:00 and 16:00 at Week 2</time_frame>
    <description>Intraocular pressure (IOP), in the study eye at 3 time-points throughout the day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>08:00, 10:00 and 16:00 at Week 6</time_frame>
    <description>Intraocular pressure (IOP), in the study eye at 3 time-points throughout the day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>08:00, 10:00 and 16:00 at Month 3</time_frame>
    <description>Intraocular pressure (IOP), in the study eye at 3 time-points throughout the day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Diurnal Intraocular Pressure</measure>
    <time_frame>Three months</time_frame>
    <description>Mean diurnal Intraocular Pressure (IOP) in the study eye at Month 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>DE-126 Opthalmic Solution 0.002% QD and Vehicle QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DE-126 Ophthalmic Solution 0.002% is administered once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol Maleate Opthalmic Solution 0.5% BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol Maleate Ophthalmic Solution 0.5% is administered twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-126 Ophthalmic Solution 0.002% QD</intervention_name>
    <description>DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning</description>
    <arm_group_label>DE-126 Opthalmic Solution 0.002% QD and Vehicle QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Maleate Ophthalmic Solution 0.5% BID</intervention_name>
    <description>Timolol Maleate Ophthalmic Solution BID (morning and evening)</description>
    <arm_group_label>Timolol Maleate Opthalmic Solution 0.5% BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been diagnosed of POAG or OHT in both eyes, or one eye with OAG and other with&#xD;
             OHT&#xD;
&#xD;
          -  Completed the required wait/washout period&#xD;
&#xD;
          -  Qualifying Day 1 IOP measurement at 3 time-points in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, nursing, or planning a pregnancy&#xD;
&#xD;
          -  Subjects who cannot safely discontinue use of ocular hypotensive medications during&#xD;
             the wait/washout period.&#xD;
&#xD;
          -  History of ocular surgery specifically intended to lower IOP in either eye. Laser&#xD;
             iridotomy in history is allowed&#xD;
&#xD;
          -  Presence of advanced glaucoma in either eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Eye Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Glaucoma Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walman Eye Center</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351-3019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Research Management</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204-2569</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Practice Management</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles, Doheny Eye Centers</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates, Inc</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacramento Eye Consultants</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815-4605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Dept. of Opthamology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hernando Eye Institute</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613-6065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901-9311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Dept. of Opthamology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bowden Eye &amp; Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shettle Eye Research</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixophthal PC dba Dixon Eye Care</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701-2363</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Clinical Research, LLC</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Eye Research of Boston, LLC</name>
      <address>
        <city>Winchester</city>
        <state>Massachusetts</state>
        <zip>01890</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Eye Care Professionals</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdvanceMed Clinical Research-Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123-2810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Jersey Eye Institute</name>
      <address>
        <city>South Orange</city>
        <state>New Jersey</state>
        <zip>07079-1855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group, P.C.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health Network Ophthamology - Oak Hollow</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262-7612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - ND</name>
      <address>
        <city>W. Fargo</city>
        <state>North Dakota</state>
        <zip>58078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Eye Clinical Research, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Mark J. Weiss MD</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104-5300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066-6412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701-7374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Specialists</name>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <zip>37803-6100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VRF Eye Specialty Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120-9411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-2168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cataract and Glaucoma Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT- Shah Research LLC dba Discovery Clinical Trials</name>
      <address>
        <city>Mission</city>
        <state>Texas</state>
        <zip>78572-2425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Eye Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215-1936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R and R Eye Research LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stacy R. Smith M.D. P.C.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117-5209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

